> ## Content Index
> Fetch the complete content index at: https://members.americanhealthintel.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Addus HomeCare buys AccentCare's personal care division for $275M
- URL: https://members.americanhealthintel.com/2026-09-15-ledger/
- Published: 2026-09-15T16:22:03.000Z
- Updated: 2026-09-15T16:22:03.000Z
- Description: Plus: Jackson Hospital emerges from bankruptcy on BCBS deal and state funding. The day's rules, money, and enforcement, sourced and tiered below.
- Author: American Health Intel

Plus: Jackson Hospital emerges from bankruptcy on BCBS deal and state funding. The day's rules, money, and enforcement, sourced and tiered below.

| American Health Intel Rules · Money · Medicine · Decoded daily The Ledger Tuesday, September 15, 2026 Addus HomeCare buys AccentCare's personal care division for $275M Plus: Jackson Hospital emerges from bankruptcy on BCBS deal and state funding. The day's rules, money, and enforcement, sourced and tiered below. ![](https://americanhealthintel.com/email/pulse-divider.png) Record Addus HomeCare, a home care company, just made the healthcare sector's biggest disclosed-price acquisition of the week, buying AccentCare's personal care division for about $275 million. The deal adds 10 states and roughly $280M in annualized revenue, a 19% bump. It lands as private equity's broader healthcare deal count heads for its lowest year since 2017. Record A 344-bed trauma center in Montgomery, Alabama just proved a governor's grant and a four-year insurance contract can pull a hospital back from bankruptcy. Jackson Hospital's exit relied on a 4-year Blue Cross Blue Shield of Alabama rate deal, a $40M state capital grant, and city and county funding on top of that. Also today Sanofi trades 20 older drugs and 3 factories for Cheplapharm equity stake [Read](https://americanhealthintel.com/editions/2026-09-15-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#sanofi-cheplapharm-mature-medicines-equity-stake) LifeStance posts 26% revenue growth, 94% adjusted EBITDA growth [Read](https://americanhealthintel.com/editions/2026-09-15-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#lifestance-health-q2-growth-jefferies-conference) 714Records$38.5BEnforcement32Deadlines186Rules [Read this issue + the trackers](https://americanhealthintel.com/editions/2026-09-15-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) Pick your field on the site and every story tells you what it means for you. Reply to this email and tell us what you want covered. We read everything. We show our work. We score our own calls. [Track record](https://americanhealthintel.com/ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Calendar](https://americanhealthintel.com/calendar/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Enforcement](https://americanhealthintel.com/enforcement/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [X](https://x.com/amhealthintel?ref=members.americanhealthintel.com) · [LinkedIn](https://www.linkedin.com/company/american-health-intel?ref=members.americanhealthintel.com) News and analysis, not legal, medical, coding, or investment advice.You subscribed at americanhealthintel.com · [Unsubscribe](%%{unsubscribe%5Furl}%%) |
| --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |